Valvular calcification and left ventricular modifying in peritoneal dialysis patients.
BACKGROUND
Cardiac valve calcification (CVC) and left ventricular (LV) alterations are frequent complication in end-stage renal disease (ESRD). We determined the prevalence of CVC and LV hypertrophy (LVH) in ESRD patients before renal replacement therapy and 12 months after peritoneal dialysis (PD).


METHODS
A prospective longitudinal of 50 incident PD patients was studied. Demographic and clinical data were recorded and blood assayed at baseline and after 1-year of follow-up. CVC and LVH were evaluated by M-mode two-dimensional echocardiography.


RESULTS
CVC of the mitral and aortic valves and of both valves were noted in 30, 18 and 10% of patients, respectively. After 12 months of PD regimen, 20% patients had aortic, 24% mitral and 8% had calcification of both valves. After one year of PD, LVH was 62 and 36% in patients with and without CVC, respectively (p < 0.05). Endothelin-1 is an independent predictor of CVC at the baseline, while nitric oxide is inversely an independent predictor at the end of follow-up.


CONCLUSIONS
CVC is associated with LVH in PD patients. These findings identified a potential role for monitored markers to be incorporated into therapeutic strategies aimed at detection and treatment of cardiovascular complications and prevention strategies.
Clinic for Nephrology and.
Damir
D
Rebić
Senija
S
Rašić
Aida
A
Hamzić-Mehmedbašić
Jasminka
J
Džemidžić
Emir
E
Kurtalić
Biomarkers; cardiac valve calcification; end-stage renal disease; left ventricular alterations; peritoneal dialysis